Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robin Foà

Showing results (1-10 of 526) with videos related to

Pageof 53
Sort By:
The New England Journal of Medicine|May 14, 2025
Ph-Positive Acute Lymphoblastic Leukemia - 25 Years of ProgressRobin Foà
Expert Review of Hematology|April 19, 2011
The European Hematology Association: strengthening hematology in Europe and beyondRobin Foà
Clinical Advances in Hematology & Oncology : H&O|August 7, 2024
Can we cure Ph+ ALL without chemotherapy or transplant?Robin Foà
Haematologica|April 12, 2005
IgVH mutations in patients with chronic lymphocytic leukemiaRobin Foà
Med (New York, N.Y.)|February 15, 2025
Always more immunotherapy in the management of B-lineage acute lymphoblastic leukemiaRobin Foà
The New England Journal of Medicine|July 12, 2014
Changes in the treatment landscape for chronic lymphoid leukemiaRobin Foà
Pediatric Reports|November 5, 2011
Acute lymphoblastic leukemia: age and biologyRobin Foà
Cancer Journal (Sudbury, Mass.)|August 16, 2021
Introduction Chronic Lymphocytic Leukemia. Where Do We Stand, Where Do We GoRobin Foà, Emili Montserrat
The New England Journal of Medicine|January 27, 2021
Dasatinib-Blinatumomab for Ph-Positive ALL. ReplyRobin Foà, Sabina Chiaretti
Haematologica|February 3, 2009
T-cell acute lymphoblastic leukemiaSabina Chiaretti, Robin Foà
Pageof 53

Showing results (1-10 of 526) with videos related to

Sort By:
Pageof 53
The New England Journal of Medicine|May 14, 2025
Ph-Positive Acute Lymphoblastic Leukemia - 25 Years of ProgressRobin Foà
Expert Review of Hematology|April 19, 2011
The European Hematology Association: strengthening hematology in Europe and beyondRobin Foà
Clinical Advances in Hematology & Oncology : H&O|August 7, 2024
Can we cure Ph+ ALL without chemotherapy or transplant?Robin Foà
Haematologica|April 12, 2005
IgVH mutations in patients with chronic lymphocytic leukemiaRobin Foà
Med (New York, N.Y.)|February 15, 2025
Always more immunotherapy in the management of B-lineage acute lymphoblastic leukemiaRobin Foà
The New England Journal of Medicine|July 12, 2014
Changes in the treatment landscape for chronic lymphoid leukemiaRobin Foà
Pediatric Reports|November 5, 2011
Acute lymphoblastic leukemia: age and biologyRobin Foà
Cancer Journal (Sudbury, Mass.)|August 16, 2021
Introduction Chronic Lymphocytic Leukemia. Where Do We Stand, Where Do We GoRobin Foà, Emili Montserrat
The New England Journal of Medicine|January 27, 2021
Dasatinib-Blinatumomab for Ph-Positive ALL. ReplyRobin Foà, Sabina Chiaretti
Haematologica|February 3, 2009
T-cell acute lymphoblastic leukemiaSabina Chiaretti, Robin Foà
Pageof 53